Threader Monorail and Threader Over the Wire Micro-Dilatation Catheters (used during angioplasty procedures) 의 리콜

Department of Health, Therapeutic Goods Administration에 따르면, 해당 리콜 는 Australia 에서 Boston Scientific Pty Ltd 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    RC-2016-RN-00612-1
  • 사례 위험등급
    Class III
  • 사례 시작날짜
    2016-05-09
  • 사례 국가
  • 사례 출처
    DHTGA
  • 사례 출처 URL
  • 비고 / 경고
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • 데이터 추가 비고
  • 원인
    Boston scientific has determined that certain threader monorail and threader over the wire micro-dilatation catheters were shipped from the australia distribution centre with an international direction for use (dfu) rather than an australian dfu. the australian dfu includes additional warnings and precautions included in the ‘precaution’ section of the dfu.
  • 조치
    Boston Scientific is providing users with the Australian DFU. This action has been closed-out on 17/02/2017.

Device

  • 모델명 / 제조번호(시리얼번호)
    Threader Monorail and Threader Over the Wire Micro-Dilatation Catheters (used during angioplasty procedures)Threader Monorail Micro-Dilatation CatheterMaterial Number (UPN): H7493926912120Batch Number:18647602Threader Over the Wire Micro-Dilatation CatheterMaterial Number (UPN): H7493927012120Batch Numbers: 18647652, 18753516, 18647655 ARTG Numbers: 259153, 259152
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source
    DHTGA